Nexus Gets FDA Approval for Procainamide HCL Injection

by Patrick Weeks

Vernon Hills, Ill., Oct. 19, 2017 — Nexus Pharmaceuticals announced today the immediate availability in the United States of Procainamide HCL Injection, USP. Nexus Pharmaceuticals’ Procainamide HCL Injection, USP is available as a multi dose vial containing 1,000 mg per 2 mL (500 mg/mL) or as a multi dose vial containing 1,000 mg per 10 mL (100 mg/mL) and is an AP Rated generic equivalent. Procainamide HCL Injection, USP is currently listed on the FDA Drug Shortage Database.

“The introduction of Procainamide HCL Injection, USP further illustrates Nexus Pharmaceuticals’ commitment to meeting market needs and shortages in the short term, while broadening the availability of effective generic products for the long term,” said Mariam Darsot, President of Nexus Pharmaceuticals Inc.

About Procainamide HCL Injection, USP

Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided.

About Nexus Pharmaceuticals Inc.

Nexus Pharmaceuticals ( is a U.S. based healthcare company that specializes in developing and marketing generic sterile injectable products. Through our high quality generic products, Nexus Pharmaceuticals is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. The company’s headquarters is in Vernon Hills, Illinois.

Media Contact
Nexus Pharmaceuticals Inc.
Zoya Ahmed

<  Read More Articles
React transport logo image only